bluebird bio, Inc. (NASDAQ:BLUE)‘s stock had its “outperform” rating reissued by equities research analysts at Leerink Swann in a research report issued on Friday. They currently have a $145.00 target price on the biotechnology company’s stock, up from their prior target price of $120.00. Leerink Swann’s price objective points to a potential upside of 13.50% from the company’s current price. Leerink Swann also issued estimates for bluebird bio’s FY2019 earnings at ($6.15) EPS and FY2020 earnings at ($1.72) EPS.

BLUE has been the topic of a number of other research reports. Zacks Investment Research downgraded shares of bluebird bio from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Cantor Fitzgerald reiterated a “sell” rating and set a $39.00 target price on shares of bluebird bio in a research report on Thursday, September 28th. Cowen and Company reiterated an “outperform” rating on shares of bluebird bio in a research report on Thursday, August 31st. Morgan Stanley boosted their target price on shares of bluebird bio from $103.00 to $105.00 and gave the company an “equal weight” rating in a research report on Monday, August 7th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $186.00 target price on shares of bluebird bio in a research report on Friday. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. bluebird bio currently has a consensus rating of “Hold” and an average target price of $113.41.

Shares of bluebird bio (NASDAQ:BLUE) opened at 127.75 on Friday. The company’s market cap is $5.82 billion. bluebird bio has a 12 month low of $37.05 and a 12 month high of $143.50. The stock’s 50 day moving average is $121.47 and its 200 day moving average is $100.75.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same quarter in the previous year, the firm earned ($1.59) EPS. The firm’s revenue was up 977.4% on a year-over-year basis. On average, analysts anticipate that bluebird bio will post ($6.85) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “bluebird bio, Inc. (BLUE) Rating Reiterated by Leerink Swann” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.watchlistnews.com/bluebird-bio-inc-blue-rating-reiterated-by-leerink-swann/1616526.html.

In related news, Director Daniel Lynch sold 500 shares of the stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $120.00, for a total transaction of $60,000.00. Following the completion of the transaction, the director now owns 3,300 shares in the company, valued at $396,000. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider David Davidson sold 4,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $131.31, for a total transaction of $525,240.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 129,379 shares of company stock valued at $15,651,533. Company insiders own 3.90% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. QS Investors LLC grew its position in bluebird bio by 70.7% during the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 500 shares during the period. Bank of Montreal Can grew its position in bluebird bio by 118.9% during the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 911 shares during the period. Turner Investments LLC bought a new position in bluebird bio during the second quarter valued at about $184,000. SG Americas Securities LLC grew its position in bluebird bio by 17.9% during the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 295 shares during the period. Finally, Fairfield Bush & CO. bought a new position in bluebird bio during the second quarter valued at about $210,000.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.